Helex

Nephrogen

This biotechnology company develops artificial intelligence-driven gene therapies to treat kidney and pancreatic diseases for patients with genetic conditions.

Alia Therapeutics

The company develops gene editing medicines for patients with genetic diseases.

Purespring Therapeutics

This company develops gene therapies for patients with chronic renal diseases to preserve kidney function and treat conditions like IgA nephropathy.

Spot Biosystems

This company develops non-viral gene therapy delivery platforms using extracellular vesicles to treat genetic diseases for pharmaceutical partners and healthcare providers.

Estuary Biotherapeutics

This biotechnology company develops targeted genetic medicines for patients with serious kidney conditions, specifically autosomal dominant polycystic kidney disease.

Nionyx Bio

The company develops adeno-associated virus gene therapies for patients with genetic kidney diseases.

Immitra Bio

This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.

CureAge

This company develops curative gene therapies for patients with neurofibromatosis type 1 and other peripheral nerve diseases using lipid nanoparticle technology.